KalVista raises $33M in series B

KalVista Pharmaceuticals Ltd. (Salisbury, U.K.) raised $33 million in a series B round led by new investor RA Capital. New investors Longwood Fund and Venrock and existing investors Novo A/S and SV Life Sciences also participated.

KalVista plans to begin Phase II trials next year of KVD001, an intravitreal plasma kallikrein inhibitor, to treat diabetic macular edema (DME). The company also expects to begin Phase I studies next year of oral kallikrein inhibitors to treat DME and hereditary angioedema (HAE). ...